PharmiWeb.com - Global Pharma News & Resources
03-Oct-2018

Global Central Nervous System Partnering Deal Trends, Players and Financials 2012-2018

Global Central Nervous System Partnering Deal Trends, Players and Financials 2012-2018

PR Newswire

DUBLIN, Oct. 3, 2018

DUBLIN, Oct. 3, 2018 /PRNewswire/ --

The "Global Central Nervous System Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Central Nervous System Partnering 2012 to 2018 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.

The report presents financial deal terms values for Central Nervous System deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Report scope

  • Trends in Central Nervous System dealmaking in the biopharma industry since 2012
  • Analysis of Central Nervous System deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Central Nervous System deal contract documents
  • Comprehensive access to over 3500 Central Nervous System deal records
  • The leading Central Nervous System deals by value since 2012
  • Most active Central Nervous System dealmakers since 2012

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Central Nervous System dealmaking

  • Central Nervous System partnering over the years
  • Central Nervous System partnering by deal type
  • Central Nervous System partnering by industry sector
  • Central Nervous System partnering by stage of development
  • Central Nervous System partnering by technology type
  • Central Nervous System partnering by therapeutic indication

Chapter 3 - Financial deal terms for Central Nervous System partnering

  • Disclosed financials terms for Central Nervous System partnering
  • Central Nervous System partnering headline values
  • Central Nervous System deal upfront payments
  • Central Nervous System deal milestone payments
  • Central Nervous System royalty rates

Chapter 4 - Leading Central Nervous System deals and dealmakers

  • Most active in Central Nervous System partnering
  • List of most active dealmakers in Central Nervous System
  • Top Central Nervous System deals by value

Chapter 5 - Central Nervous System contract document directory

  • Central Nervous System partnering deals where contract document available

Chapter 6 - Central Nervous System dealmaking by therapeutic target

  • Deals by Central Nervous System therapeutic target

Appendices

Appendix 1 - Directory of Central Nervous System deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Central Nervous System deals by deal type 2012 to 2018
Appendix 3 - Directory of Central Nervous System deals by stage of development 2012 to 2018
Appendix 4 - Directory of Central Nervous System deals by technology type 2012 to 2018

For more information about this report visit https://www.researchandmarkets.com/research/p8g5lc/global_central?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-central-nervous-system-partnering--deal-trends-players-and-financials-2012-2018-300723584.html

SOURCE Research and Markets

Editor Details

Last Updated: 03-Oct-2018